House committee plans to examine FDA's drug-safety efforts

03/4/2010 | Reuters

The House Energy and Commerce Committee scheduled a hearing Wednesday to look into the FDA's drug-safety efforts amid criticism that the agency is slow to respond to reports of adverse reactions to approved treatments. Deputy FDA Commissioner Joshua Sharfstein will appear before a health subcommittee as part of the inquiry.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX